Trial Profile
A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms GALAXY-1
- Sponsors Synta Pharmaceuticals
- 09 Feb 2019 This trial has been discontinued in United kingdom.
- 06 Aug 2015 According to a Synta Pharmaceuticals media release, data from this study were published in the first issue of the journal Annals of Oncology.
- 08 May 2014 Status changed from active, no longer recruiting to completed as reported by a Synta Pharmaceuticals media release.